Abstract
Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson's disease. Here we identify inhibitors of LRRK2 kinase that are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration. These results establish that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for the treatment of Parkinson's disease.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Humans
-
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
-
Mutation
-
Neurons / physiology
-
Parkinson Disease / genetics
-
Parkinson Disease / prevention & control*
-
Phosphorylation
-
Protein Kinase Inhibitors / pharmacology
-
Protein Serine-Threonine Kinases / antagonists & inhibitors*
-
Protein Serine-Threonine Kinases / drug effects
-
Protein Serine-Threonine Kinases / genetics
-
Protein Serine-Threonine Kinases / toxicity
Substances
-
Protein Kinase Inhibitors
-
LRRK2 protein, human
-
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
-
Protein Serine-Threonine Kinases